Premier Alternatives

Genfleet (HKG: 02595)

Shanghai, China · Founded 2017 · Publicly Held

GenFleet Therapeutics (Shanghai) Inc is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology, covering different lines of treatments of multiple solid… Genfleet (HKG: 02595) is based in Shanghai, China and was founded in 2017. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $800 million (Sep 2025). It has raised $205 million.

Last price · $/share
—
Implied valuation
$799.7M
Total raised
$204.8M
Last round
—

Genfleet (HKG: 02595) key facts

  • GenFleet Therapeutics (Shanghai) Inc is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology, covering different lines of treatments of multiple solid…
  • Genfleet (HKG: 02595)’s last known valuation is $799.7M (Sep 2025).
  • It has raised $204.8M; the latest was Later Stage VC in Mar 2026.
  • Notable investors include OrbiMed, Suzhou Guofa Venture Capital, CITIC Capital, Lake Bleu Capital, China Universal Asset Management — 10 tracked in total.
  • Status: Publicly Held.
Free account
More of Genfleet (HKG: 02595) with a free account
  • ·Watch Genfleet (HKG: 02595): the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Genfleet (HKG: 02595) funding rounds

No rounds on record

No funding rounds for Genfleet (HKG: 02595) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Genfleet (HKG: 02595) valuation

Genfleet (HKG: 02595) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $800 million (Sep 2025). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.

Genfleet (HKG: 02595) investors

10 investors are on record for Genfleet (HKG: 02595), including OrbiMed, Suzhou Guofa Venture Capital, CITIC Capital and Lake Bleu Capital. By type, the record holds 2 hedge funds, 2 asset managers and 1 growth equity firm.

About Genfleet (HKG: 02595)

GenFleet Therapeutics (Shanghai) Inc is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology, covering different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases. It has established a product pipeline consisting of eight product candidates with five under clinical development, including two Core Products - GFH925 and GFH375. GFH925 is an in-house discovered new drug, has been approved for commercialization in China for the treatment of advanced non-small cell lung cancer.

Sector
Healthcare
HQ
Shanghai, China
Founded
2017
Employees
68
Ownership
Publicly Held

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$799.7M

Genfleet (HKG: 02595)’s last known valuation, Sep 2025. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.